Intellect Neurosciences, Pfizer neurology news

Intellect Neurosciences filed a suit in the New York State Supreme Court alleging that Pfizer breached a license deal covering Intellect's Antisenilin mAb platform technology. In May, the U.S. Patent and Trademark Office granted Intellect a patent covering Antisenilin mAbs that bind to beta amyloid while sparing the amyloid precursor protein (APP) for the treatment and prevention of Alzheimer's disease. Intellect alleges that the patent issuance triggered a $2 million milestone payment from Pfizer under the terms of a 2008 deal between the parties. Intellect said that the pharma does not believe that the milestone payment is due under the deal. The parties could not be reached for comment. ...